Download presentation
Presentation is loading. Please wait.
Published byJulie Rancourt Modified over 5 years ago
1
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa De Carlo, MD Journal of Thoracic Oncology Volume 12, Issue 11, Pages e181-e182 (November 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 (A) Variant allelic frequency of mutations (MUTs) detected in EGFR and BRAF in cell-free DNA isolated from plasma of the patient by next-generation sequencing at the indicated times. (asterisk indicates % variant allelic frequency). (B) Amplification refractory mutation system polymerase chain reaction for BRAF V600E performed on the same liquid biopsy samples to confirm BRAF mutation. Red squares indicate positive amplification of V600E mutant. (Upper band) DNA amplification control (CTRL). (Lower band) Wild-type (WT) (not mutated) amplification. Abbreviations: ND, not detected; L, ladder; Jan, January; NTC, no template control; bp, base pair. Journal of Thoracic Oncology , e181-e182DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.